Combination of Fedratinib and Decitabine for Myeloproliferative Neoplasms (MPN)- Accelerated Phase (AP)/Blast Phase (BP)
Status:
Recruiting
Trial end date:
2025-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this research is to study the safety and tolerability and to establish the
maximum tolerated dose (MTD) of the combination of two drugs, fedratinib and decitabine, for
the treatment of advanced-phase MPNs.